AU2012296266B2 - Cardiovascular therapeutics - Google Patents

Cardiovascular therapeutics Download PDF

Info

Publication number
AU2012296266B2
AU2012296266B2 AU2012296266A AU2012296266A AU2012296266B2 AU 2012296266 B2 AU2012296266 B2 AU 2012296266B2 AU 2012296266 A AU2012296266 A AU 2012296266A AU 2012296266 A AU2012296266 A AU 2012296266A AU 2012296266 B2 AU2012296266 B2 AU 2012296266B2
Authority
AU
Australia
Prior art keywords
gly
ala
leu
val
lie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012296266A
Other languages
English (en)
Other versions
AU2012296266A1 (en
Inventor
Christopher John Charles
Christopher Joseph Pemberton
Arthur Mark Richards
Maithri SIRIWARDENA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otago Innovation Ltd
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of AU2012296266A1 publication Critical patent/AU2012296266A1/en
Assigned to OTAGO INNOVATION LIMITED reassignment OTAGO INNOVATION LIMITED Request for Assignment Assignors: CHARLES, CHRISTOPHER, OTAGO INNOVATION LIMITED, PEMBERTON, CHRISTOPHER, RICHARDS, ARTHUR, SIRIWARDENA, Maithri
Application granted granted Critical
Publication of AU2012296266B2 publication Critical patent/AU2012296266B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2012296266A 2011-08-18 2012-08-17 Cardiovascular therapeutics Ceased AU2012296266B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525140P 2011-08-18 2011-08-18
US61/525,140 2011-08-18
PCT/IB2012/002117 WO2013024362A2 (en) 2011-08-18 2012-08-17 Cardiovascular therapeutics

Publications (2)

Publication Number Publication Date
AU2012296266A1 AU2012296266A1 (en) 2014-03-13
AU2012296266B2 true AU2012296266B2 (en) 2017-08-31

Family

ID=47715527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012296266A Ceased AU2012296266B2 (en) 2011-08-18 2012-08-17 Cardiovascular therapeutics

Country Status (8)

Country Link
US (2) US9783574B2 (enExample)
EP (1) EP2744506B1 (enExample)
JP (1) JP6222779B2 (enExample)
CN (1) CN103889438B (enExample)
AU (1) AU2012296266B2 (enExample)
CA (1) CA2845617A1 (enExample)
SG (2) SG11201400067TA (enExample)
WO (1) WO2013024362A2 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007617A1 (en) * 1999-07-22 2001-02-01 Knoll Gmbh Human homologue of bovine neuroendocrine secretory protein, nesp55, polynucleotides and uses thereof linked with obesity
WO2005072055A2 (en) * 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155590A (en) 1962-08-02 1964-11-03 Ncr Co Encapsulation process and its product
US3488418A (en) 1965-11-18 1970-01-06 Sterling Drug Inc Sustained relief analgesic composition
US3391416A (en) 1966-07-14 1968-07-09 Wollard Aircraft Service Equip Conveyance loader system
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP4181232B2 (ja) 1997-07-18 2008-11-12 帝國製薬株式会社 ジクロフェナクナトリウム含有油性外用貼付製剤
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6410041B1 (en) 1998-04-28 2002-06-25 Trustees Of Tufts College Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine
AU760735B2 (en) 1998-09-28 2003-05-22 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US20050171021A1 (en) * 1998-11-12 2005-08-04 Cormier Michel J. Buffered drug formulations for transdermal
US6309380B1 (en) 1999-01-27 2001-10-30 Marian L. Larson Drug delivery via conformal film
US6273831B1 (en) * 1999-09-03 2001-08-14 Callaway Golf Company Golf club head with a polymer insert
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
WO2008030122A1 (en) * 2006-09-07 2008-03-13 University Of Otago Biomarkers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007617A1 (en) * 1999-07-22 2001-02-01 Knoll Gmbh Human homologue of bovine neuroendocrine secretory protein, nesp55, polynucleotides and uses thereof linked with obesity
WO2005072055A2 (en) * 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RUIZ-GOMEZ, G. et al., 'Structure-Activity Relationships for Substrate-Based Inhibitors of Human Complement Factor B', Journal of Medicinal Chemistry. 2009, vol. 52, issue 19, pages 6042-6052. *
SAITO, K. et al., 'Antioxidative Properties of Tripeptide Libraries Prepared by the Combinatorial Chemistry', Journal of Agricultural and Food Chemistry. 2003, vol. 51, no. 12, pages 3668-3674. *
STADLBAUER, S. et al., 'Utilizing Reversible Copper(II)Peptide Coordination in a Sequence-Selective Luminescent Receptor', Chemistry - A European Journal. 2008, vol. 14, no. 8, pages 2536-2541. *

Also Published As

Publication number Publication date
CN103889438B (zh) 2016-08-24
WO2013024362A2 (en) 2013-02-21
JP2014524435A (ja) 2014-09-22
JP6222779B2 (ja) 2017-11-01
AU2012296266A1 (en) 2014-03-13
US20180148475A1 (en) 2018-05-31
SG11201400067TA (en) 2014-04-28
CA2845617A1 (en) 2013-02-21
WO2013024362A3 (en) 2013-07-25
CN103889438A (zh) 2014-06-25
US20130072431A1 (en) 2013-03-21
EP2744506B1 (en) 2019-10-09
EP2744506A2 (en) 2014-06-25
US9783574B2 (en) 2017-10-10
NZ621790A (en) 2017-09-29
SG10201601086WA (en) 2016-03-30
EP2744506A4 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
JP2019104768A (ja) 代謝性症候群を予防し又は治療するための方法
CN101296704B (zh) 用于减少cd36表达的方法
JP6918046B2 (ja) バース症候群の予防または治療のための方法及び組成物
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
KR20210093958A (ko) 미토콘드리아 질환을 표적으로 하는 유사체
KR20150065736A (ko) 안지오텐신의 경구 제형
US8557958B1 (en) Compositions and methods for treatment of diabetes
EP2744506B1 (en) Cardiovascular therapeutics
US20180008664A1 (en) Novel peptides and peptidomimetics
NZ621790B2 (en) Cardiovascular therapeutics
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
WO2025123051A1 (en) Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain
HK1242610A1 (en) Methods for reducing cd36 expression
HK1197994B (en) Methods for reducing cd36 expression
HK1173367B (en) Methods for reducing cd36 expression
HK1123992B (en) Methods for reducing cd36 expression
HK1212718B (zh) 用於减少cd36表达的方法
HK1179977A (en) Aromatic-cationic peptides and uses of same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: OTAGO INNOVATION LIMITED

Free format text: FORMER APPLICANT(S): PEMBERTON, CHRISTOPHER; OTAGO INNOVATION LIMITED; CHARLES, CHRISTOPHER; RICHARDS, ARTHUR; SIRIWARDENA, MAITHRI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired